SAN 300

Drug Profile

SAN 300

Alternative Names: Anti-VLA-1 antibody - Salix; Anti-VLA-1 mAb; SAN-300

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biogen Idec
  • Developer Salix Pharmaceuticals
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Integrin alpha1beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 23 Mar 2017 Valeant completes a phase II trial in Rheumatoid arthritis (Treatment-experienced) in USA (SC) (NCT02047604)
  • 15 Dec 2016 Biomarkers information updated
  • 15 Jan 2016 Phase-II development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top